Lindbrook Capital’s Gyre Therapeutics GYRE Stock Holding History

Lindbrook Capital’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-533	Closed	-$20K	–	1946
2021 Q1	$20K	Buy	+533	New	+$24.4K	﹤0.01%	753

Other funds holding GYRE

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Lindbrook Capital's GYRE Position: Q2 2021 in Review

Lindbrook Capital sold out of Gyre Therapeutics (GYRE) in Q2 2021, closing a stake of 533 shares — an estimated $20K sold.

Lindbrook Capital first reported a position in GYRE in Q1 2021 and held it in 1 quarter. The position peaked at $20K in Q1 2021. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

Lindbrook Capital reported no remaining Gyre Therapeutics position as of Q2 2021 after selling out during the quarter.
Lindbrook Capital sold 533 Gyre Therapeutics shares in Q2 2021, an estimated $20K.
Lindbrook Capital first reported a position in Gyre Therapeutics in Q1 2021 and held it in 1 quarter.
Lindbrook Capital's Gyre Therapeutics position peaked at $20K in Q1 2021.
69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on Lindbrook Capital's 13F filing for Q2 2021, filed 27 Jul 2021.